Cerebral vascular dysfunction during hypercholesterolemia

Stroke

Volumn 38, Issue 7, 2007, Pages 2136-2141

  Kitayama, Jiro ^a   Faraci, Frank M ^a   Lentz, Steven R ^a   Heistad, Donald D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Cerebral arterioles; Endothelium; Hypercholesterolemia; Oxidative stress; Vasomotor function

Indexed keywords

APOLIPOPROTEIN E; NITROPRUSSIDE SODIUM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BRAIN ARTERY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME SUBSTRATE; FEMALE; HISTOLOGY; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; INTIMA; LIPID DIET; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VASOMOTOR REFLEX;

ACETOPHENONES; ACETYLCHOLINE; ANIMALS; ANTIOXIDANTS; AORTA; APOLIPOPROTEINS E; ARTERIOLES; CEREBROVASCULAR CIRCULATION; CHOLESTEROL; CYCLIC N-OXIDES; DIETARY FATS; ENDOTHELIUM, VASCULAR; FEMALE; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NADP; NITROPRUSSIDE; OXIDATIVE STRESS; SPIN LABELS; SUPEROXIDES; VASODILATION; VASODILATOR AGENTS;

EID: 34347333472     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.481879     Document Type: Article

References (40)

1. Amarenco P, Tonkin AM. Statins for stroke prevention: disappointment and hope. Circulation. 2004;109(suppl III):III-44-III-49.
2. Demchuk AM, Hess DC, Brass LM, Yatsu FM. Is cholesterol a risk factor for stroke? yes. Arch Neurol. 1999;56:1518-1520.
3. Landau WM. Is cholesterol a risk factor for stroke? no. Arch Neurol. 1999;56:1521-1524.
4. Kannel WB, Dawber TR, Cohen ME, McNamara PM. Vascular disease of the brain - epidemiologic aspects: the Framingham Study. Am J Public Health. 1965;55:1355-1366.
5. Kagan A, Popper JS, Rhoads GG. Factors related to stroke incidence in Hawaiian Japanese men: the Honolulu Heart Study. Stroke. 1980;11:14-21.
6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
8. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein C, Cuddy E, Moyé LA, Piller LB, Rutherford J, Simpson LM, Braunwald E, for the CARE Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol And Recurrent Events (CARE) study. Circulation. 1999;99:216-223.
9. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
11. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RGJ, on behalf of the PROSPER group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623-1630.
12. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-844.
13. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res. 1996;33:181-194.
14. d'Uscio LV, Smith LA, Katusic ZS. Hypercholesterolemia impairs endothelium-dependent relaxations in common carotid arteries of apolipoprotein E-deficient mice. Stroke. 2001;32:2658-2664.
15. d'Uscio LV, Baker TA, Mantilla CB, Smith L, Weiler D, Sieck GC, Katusic ZS. Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:1017-1022.
16. Rossitch E Jr, Alexander E 3rd, Black PM, Cooke JP. L-Arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. J Clin Invest. 1991;87:1295-1299.
17. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Reg Integr Comp Physiol. 2003;285:R277-R292.
18. Didion SP, Faraci FM. Effects of NADH and NADPH on superoxide levels and cerebral vascular tone. Am J Physiol. 2002;282:H688-H695.
19. Paravicini TM, Chrissobolis S, Drummond GR, Sobey CG. Increased NADPH-oxidase activity and Nox4 expression during chronic hypertension is associated with enhanced cerebral vasodilatation to NADPH in vivo. Stroke. 2004;35:584-589.
20. Bonthu S, Heistad DD, Chappell DA, Lamping KG, Faraci FM. Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. Arteriolscler Thromb Vasc Biol. 1997;17:2333-2340.
21. Elhage R, Arnal JF, Pieraggi MT, Duverger N, Fiévet C, Faye JC, Bayard F. 17β-Estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 1997;17:2679-2684.
22. Didion SP, Lynch CM, Baumbach GL, Faraci FM. Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes. Stroke. 2005;36:342-347.
23. Sobey CG, Faraci FM. Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles. Stroke. 1997;28:837-842.
24. Kauser K, da Cunha V, Fitch R, Mallari C, Rubanyi GM. Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Physiol. 2000;278:H1679-H1685.
25. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Lüscher TF, Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997;99:41-46.
26. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Lüscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 1998;97:2494-2498.
27. Quyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III. Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest. 1995;95:1747-1755.
28. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000;20:1557-1564.
29. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546-2551.
30. Stokes KY, Clanton EC, Russel JM, Ross CR, Granger DN. NAD(P)H oxidase-derived superoxide mediates hypercholesterolemia-induced leukocyte-endothelial cell adhesion. Circ Res. 2001;88:499-505.
31. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Bräsen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Böhm M, Meinertz T, Münzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027-2033.
32. Pritcherd KA Jr, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, Stemerman MB. Native low density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res. 1995;77:510-518.
33. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000;20:2175-2183.
34. Paravicini TM, Sobey CG. Cerebral vascular effects of reactive oxygen species: recent evidence for a role of NADPH-oxidase. Clin Exp Pharmacol Physiol. 2003;30:855-859.
35. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, Iadecola C. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res. 2004;95:1019-1026.
36. Park L, Anrather J, Zhou P, Frys K, Wang G, Iadecola C. Exogenous NADPH increases cerebral blood flow through NADPH oxidase-dependent and -independent mechanisms. Arterioscler Thromb Vasc Biol. 2004;24:1860-1865.
37. + channel inhibition by reactive oxygen species. Am J Physiol Cell Physiol. 2002;282:C461-C471.
38. Fukai T, Galis ZS, Meng XP, Parthasarathy S, Harrison DG. Vascular expression of extracellular superoxide dismutase in atherosclerosis. J Clin Invest. 1998;101:2101-2111.
39. Yaghoubi M, Oliver-Krasinski J, Cayatte AJ, Cohen RA. Decreased sensitivity to nitric oxide in the aorta of severely hypercholesterolemic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2000;36:751-757.
40. Didion SP, Heistad DD, Faraci FM. Mechanisms that produce nitric oxide-mediated relaxation of cerebral arteries during atherosclerosis. Stroke. 2001;32:761-766.